NVS — Healthcare Leader Building StructureNovartis is showing an interesting structure within the Healthcare sector.
After a strong prior uptrend, price has been consolidating inside a clear range between roughly 142 and 155. The lower boundary around 141.96 has acted as an important support area, while the upper range near 155–156 is the
Compare with Novartis AG
7.06 USD
14.06 B USD
54.81 B USD
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Profile
Sector
Industry
CEO
Vasant Narasimhan
Website
Headquarters
Basel
Founded
1996
IPO date
May 7, 2001
ISIN
US66987V1098
CUSIP
66987V109
FIGI
BBG000LYF3S8
Identifiers
ISIN US66987V1098
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Novartis Wave Analysis – 10 December 2025- Novartis reversed from strong resistance level 133.35
- Likely to fall to support level 128.00
Novartis recently reversed up from the resistance area between the strong resistance level 133.35 (which has been reversing the price from the start of October) and the upper daily Bollinger Band.
The
Novartis Increases Purchase of Avidity BiosciencesNovartis Strengthens Its Rare Diseases Strategy with the Purchase of Avidity Biosciences
By Ion Jauregui – Analyst at ActivTrades
Novartis (SWX: NOVN) has taken an important step to strengthen its presence in therapies for rare diseases. The company announced the acquisition of Avidity Bioscien
Novartis Wave Analysis –5 September 2025
- Novartis broke resistance area
- Likely to rise to resistance level 132.00
Novartis recently opened with a sharp upward gap breaking the resistance area between the resistance level 128.00 (top of the previous impulse wave iii) and the resistance trendline of the daily up channel from May.
The
Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is
NVS 1H Swing Long Conservative Trend TradeConservative Trend Trade
+ long impulse
+ 1/2 correction
+ T2 level
+ support level
- biggest volume 2Sp-
Calculated affordable stop limit
1 to 2 R/R within 1H range take profit
Daily Trend
"+ long impulse
+ 1/2 correction
+ JOC level
+ support level
- above 1/2 of entire 1D wave at the support le
Investing in Health: Reasons Why Novartis AG Stock Stands OutIn an era where health is wealth, and the global healthcare sector is booming like never before, savvy investors are looking for opportunities that promise growth and a meaningful impact on people’s lives. Enter Novartis AG—a powerhouse in pharmaceuticals that’s not only redefining treatments but al
NVS Novartis AG Options Ahead of EarningsAnalyzing the options chain and the chart patterns of NVS Novartis AG prior to the earnings report this week,
I would consider purchasing the 110usd strike price Calls with
an expiration date of 2024-8-16,
for a premium of approximately $3.30.
If these options prove to be profitable prior to the ear
Novartis Strikes $1.01 Bln Deal with Arvinas for Prostate DrugsNovartis ( NYSE:NVS ), the Swiss pharmaceutical giant, has made a strategic move in the field of cancer treatment by securing a licensing agreement with Arvinas, a U.S. biotech company. The deal, valued at up to $1.01 billion, grants Novartis access to Arvinas' experimental prostate cancer drug, ARV
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
5.694% YTM
Maturity dateMar 18, 2056
Coupon5.70% (Fixed)
5.690% YTM
Maturity dateNov 5, 2055
Coupon5.30% (Fixed)
5.646% YTM
Maturity dateMar 18, 2046
Coupon5.60% (Fixed)
5.624% YTM
Maturity dateAug 14, 2050
Coupon2.75% (Fixed)
5.566% YTM
Maturity dateNov 5, 2045
Coupon5.20% (Fixed)
5.559% YTM
Maturity dateMay 6, 2044
Coupon4.40% (Fixed)
5.558% YTM
Maturity dateNov 20, 2045
Coupon4.00% (Fixed)
5.531% YTM
Maturity dateSep 18, 2054
Coupon4.70% (Fixed)
5.493% YTM
Maturity dateSep 21, 2042
Coupon3.70% (Fixed)
5.052% YTM
Maturity dateMar 18, 2036
Coupon4.90% (Fixed)
4.976% YTM
Maturity dateNov 5, 2035
Coupon4.60% (Fixed)
See all NVS bonds
Weight0.68%
Market value137.92 M
Weight0.79%
Market value111.40 M
Weight0.66%
Market value110.62 M
Weight10.43%
Market value98.86 M
Weight0.57%
Market value98.71 M
Weight1.46%
Market value89.31 M
Weight0.68%
Market value81.36 M
Weight5.02%
Market value67.17 M
Weight5.02%
Market value67.17 M
Weight5.02%
Market value67.17 M
Weight0.40%
Market value32.45 M
Explore more ETFs









